▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

Zephyr AI Presents the Development of a Novel AI-Enabled Composite Biomarker Effective in Predicting Sensitivity to PARP Inhibition in Late-line Cancer Patients

Zephyr AI, a high-growth healthcare technology company committed to developing AI-Enabled Composite Biomarkers to expand the horizon of precision medicine in cancer drug development, presented a poste...

Business Wire

Expanding the Horizons of Precision Medicine

MCLEAN, Va.: Zephyr AI, a high-growth healthcare technology company committed to developing AI-Enabled Composite Biomarkers to expand the horizon of precision medicine in cancer drug development, presented a poster today at the Annual Meeting for the American Society of Clinical Oncology (ASCO). Entitled “Evaluation of a novel signature for PARP inhibitor sensitivity prediction using real-world data,” the presentation demonstrates the game-changing patient insights that AI can derive from complex and diverse data sets that can be used to predict a patient's sensitivity to a class of medicines called poly ADP ribose polymerase (PARP) inhibitors.

PARP inhibitors are currently authorized for use in the treatment of cancers that exhibit homologous recombination repair deficiencies (HRD+) or mutations in the breast cancer gene (BRCA) 1 or 2. These biomarkers are predominantly present in patients diagnosed with breast, ovarian, prostate, and pancreatic cancer and can predispose patients to PARP inhibitor sensitivity. However, recent data, across this class of medicines have revealed that their benefit-risk profile in late-line ovarian cancer patients using these biomarkers is insufficient to support their continued prescription. As such, these drug labels have recently been withdrawn creating a critical unmet need in late-line ovarian cancer patients to access this class of agent with the appropriate biomarker in place.

The Zephyr AI team has developed a novel, next-generation biomarker that could be used to identify late-line patients whose tumors harbor latent sensitivities to the PARP inhibitor olaparib, distinct from HRD+ and BRCA mutations. The team resolved this novel composite biomarker by using its custom machine learning (ML) foundation model developed over the last several years. This novel AI-enabled composite biomarker was validated using a real world cohort of ovarian cancer patients that had received olaparib in diverse drug combinations, typically, as a late-line therapy.

“Zephyr’s ML technology has the ability to precipitate a stepchange in patient enrichment approaches for new drugs emerging in oncology, an area where historically many drugs have failed or we have needed to refine our knowledge slowly and empirically,” said Jeff Sherman Co-Founder, Interim CEO, and Chief Technology Officer at Zephyr.

Zephyr validated its drug response predictions for this cohort using clinico-genomics and patient outcomes data. This analysis revealed that for patients predicted to be sensitive based on the Zephyr model a statistically significant improvement in real-world progression free survival from 24 months to more than 60 months (rw-PFS hazard ratio of 2.04 with a p-value less than 0.001) and a rw-overall survival improvement from 23 months to more than 60 months (rw-OS hazard ratio of 3.37 with a p-value less than 0.005) was observed. This profile was in contrast to analysis using the conventional HRD+ biomarker in the same cohort, where there was no statistically significant improvement in either of the clinically relevant, real-world end points reported.

“It is exciting to be able to share one of the applications of our ML foundation model that the team at Zephyr has been building. We anticipate that the assembly of enormous and complex multi-model data sets into a neural network that forms the basis of our foundation model will enable a new, composite approach to biomarkers broadly. This model will reveal novel insights across many mechanisms of action as we increase the breadth of training data provided to these models,” said Rachael Brake, PhD, Zephyr AI’s Chief Scientific Officer. “We believe that by looking beyond HRD+ and ‘BRCAness,’ we can uncover novel and latent drivers of PARP inhibitor sensitivity. This coincides with many next-generation PARP inhibitors entering clinical development and we are excited to partner with these drug development teams to increase the reach and probability of success of this important class of medicine.”

About Zephyr AI

Zephyr AI is a high-growth healthcare technology company committed to radically reshaping precision medicine in oncology and cardiometabolic disease. Through partnerships and proprietary data, Zephyr AI is curating the world’s most comprehensive healthcare dataset and marrying it with cutting-edge artificial intelligence algorithms to generate novel, translatable insights to build tools and products that support patients and providers and fuel ongoing research. At Zephyr AI, our mission-focused team of world-class software engineers and biologists leverage big data and next-generation technology to derive transformational insights and build enduring partnerships that will revolutionize the treatment of cancer and cardiometabolic disease. Visit us at www.zephyrai.bio and follow us on LinkedIn.

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

RSA at Cybertech Europe 2024

Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…

Italian Security Awards 2024: G11 Media honours the best of Italian cybersecurity

G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes

How Austria is making its AI ecosystem grow

Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries

Sparkle and Telsy test Quantum Key Distribution in practice

Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

Most read

Roblox to Report Second Quarter 2025 Financial Results on July 31, 2025

Roblox Corporation (NYSE: RBLX) today announced that it will report the company’s second quarter 2025 financial results before the opening of the U.S.…

NiCE Unveils 2025 International CX Excellence Award Winners, Spotlighting…

#AI--NiCE (Nasdaq: NICE) today announced the winners of its 2025 International CX Excellence Awards, honoring organizations from across EMEA and APAC…

LambdaTest Announces Deeper Collaboration with Appium as Strategic Partnership

#AI--LambdaTest, a unified agentic AI and cloud engineering platform, has announced it has become a strategic sponsor of Appium, the world’s most widely…

ReSource Pro Makes Strategic Acquisition of Propellint; Expands Technology…

ReSource Pro today announced it has acquired Propellint, a technology services firm specializing in implementation and support for insurance platforms…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!